TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

By

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

By

TScan Therapeutics to Participate in Upcoming Investor Conferences

By

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces Updates to its Board of Directors

By

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

By

TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

By

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

By